Market Exclusive

Analyst Activity – Stifel Nicolaus Reiterates Buy on Aerie Pharmaceuticals (NASDAQ:AERI)

Analyst Ratings For Aerie Pharmaceuticals (NASDAQ:AERI)

Today, Stifel Nicolaus reiterated its Buy rating on Aerie Pharmaceuticals (NASDAQ:AERI) with a price target of $70.00.

There are 1 hold rating, 11 buy ratings on the stock.

The current consensus rating on Aerie Pharmaceuticals (NASDAQ:AERI) is Buy (Score: 2.92) with a consensus target price of $66.08 per share, a potential 21.92% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Aerie Pharmaceuticals (NASDAQ:AERI)
Aerie Pharmaceuticals (NASDAQ:AERI) has insider ownership of 9.36% and institutional ownership of 92.01%.

Recent Trading Activity for Aerie Pharmaceuticals (NASDAQ:AERI)
Shares of Aerie Pharmaceuticals closed the previous trading session at 54.20 down -0.50 -0.91% with 277,083 shares trading hands.

Exit mobile version